Sponsor

iTeos Therapeutics

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name iTeos Therapeutics appears in 4 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials4
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

4 shown
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung CancerNCT05403385 · lead sponsor · 2022-08-26
ACTIVE_NOT_RECRUITING
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)NCT06472076 · collaborator · 2024-06-10
ACTIVE_NOT_RECRUITING
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerNCT05565378 · collaborator · 2022-10-14
ACTIVE_NOT_RECRUITING
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsNCT05060432 · collaborator · 2021-09-06
UNKNOWN

Sponsor roles

collaborator3
lead sponsor1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.